MedTrace Logo

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

NCT04694846 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2025-09-09

No results posted yet for this study

Summary

This trial studies how well an enhanced tobacco intervention protocol (ETIP) works compared to standard treatment in helping head and neck and lung cancer patients starting treatment to reduce cigarette use. ETIP is an evidence-based tobacco cessation program including specialized one-to-one and telehealth counseling, drug therapy, nicotine replacement therapy, and frequent patient follow up. ETIP may help reduce smoking and improve cessation in patients with head and neck squamous cell cancer or non-small cell lung cancer.

Conditions

Interventions

DRUG

Nicotine Replacement

Given NRT via trans-dermal patch, gum, nasal spray, inhaler or lozenges

DRUG

Bupropion Hydrochloride Controlled-release

Given PO

DRUG

Varenicline

Given PO

OTHER

Tobacco Cessation Counseling

Receive counseling

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Quality of Life Assessment

Ancillary studies

OTHER

Best Practice

Receive standard treatment

Sponsors & Collaborators

  • Thomas Jefferson University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-19
Primary Completion
2024-08-16
Completion
2024-08-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04694846 on ClinicalTrials.gov